VeriSIM Life utilizes an AI-driven computational bioplatform to predict clinical outcomes of drug candidates by integrating chemical and biological modeling with machine learning techniques. This approach addresses the inefficiencies and inaccuracies in drug development, enabling pharmaceutical companies to allocate resources more effectively and increase the likelihood of clinical success.
Funding
$21.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
MVFounders
Product
Problem
The traditional drug development process is inefficient and inaccurate, leading to high failure rates in clinical trials and wasted resources for pharmaceutical companies. Identifying promising drug candidates early and predicting their clinical outcomes remains a significant challenge.
Solution
VeriSIM Life offers an AI-driven computational bioplatform, BIOiSIM, that predicts clinical outcomes of drug candidates by integrating chemical and biological modeling with machine learning techniques. BIOiSIM provides a Translational Index, predicting how drugs will affect patients, optimizing portfolio management, and increasing clinical success. The platform analyzes billions of potential simulation scenarios to identify lead compounds and de-risk R&D, enabling pharmaceutical companies to allocate resources more effectively and accelerate the development of groundbreaking therapies. By providing actionable insights, BIOiSIM helps guide critical decision-making and streamlines the drug development pipeline.
Target Audience
The primary customers are pharmaceutical companies, biotechs, and academic & research institutions involved in drug discovery and development.
Features
- AI-driven decision engine combining chemical and biological modeling with AI and ML techniques
- Translational Index predicting drug effects on patients
- Inferential search space of 1 billion drug-like compounds
- 10 billion network effects spawned in deep learning algorithms
- 800 billion total potential simulation scenarios computational capacity
- 1.5 million real and robust validation simulations
- AI-powered predictions based on structure-only inputs